Inicure lead compound characterised as a specific agonist for FPR1, which displays a biased signalling profile that leads to a functional selective activating of the human neutrophils class (https://doi.org/10.1002/JLB.2HI0520-317R).
Functional selective FPR1 signaling in favor of an activationof the neutrophil superoxide generating NOX2 complex
Immunotherapies & Innovations for Infectious Diseases Congress (I4ID2025) – Lyon France
Invited as presenter at the Immunotherapies & Innovations for Infectious Diseases Congress (#I4ID2025) – in Lyon, CEO of
Nordic Life Science Days 2025 Göteborg Sweden
Chairman Dr Sara Malcus and CEO Peter Olofsson-Sahl participated in the Nordic Life Science days. Reconnecting with several
Lead optimisation support from Scilife DDD
Inicures founders and researchers Professor Johan Bylund at the University of Gothenburg, together with Dr. Peter Olofsson-Sahl at